HC Wainwright Reaffirms “Buy” Rating for Personalis (NASDAQ:PSNL)

Personalis (NASDAQ:PSNL)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $11.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 83.95% from the stock’s current price.

Separately, Needham & Company LLC reissued a “buy” rating and set a $7.25 target price on shares of Personalis in a research note on Friday, December 20th.

Personalis Price Performance

PSNL stock opened at $5.98 on Wednesday. The company has a fifty day moving average price of $4.68 and a 200 day moving average price of $4.31. Personalis has a 12 month low of $1.12 and a 12 month high of $7.20. The company has a market cap of $422.48 million, a price-to-earnings ratio of -3.56 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. During the same quarter last year, the firm earned ($0.51) EPS. As a group, analysts anticipate that Personalis will post -1.41 earnings per share for the current year.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new position in Personalis in the 3rd quarter valued at about $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in shares of Personalis by 42.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after buying an additional 4,504 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Personalis by 438.0% during the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after buying an additional 17,082 shares during the period. Quantbot Technologies LP acquired a new stake in Personalis during the third quarter worth approximately $210,000. Finally, Barclays PLC grew its stake in Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after acquiring an additional 20,444 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.